Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2025-04-07 Major Shareholding Noti…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a change in shareholding (flagging notification). It details the threshold crossing of Avanza Bank Holding AB's ownership in Immunovia AB. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-04-07 Swedish
Annual Report (ESEF) 2024
Annual Report (ESEF) Classification · 1% confidence FY 2024
2025-04-02 Swedish
The exercise period for warrants series TO 3 begins today
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the commencement of an exercise period for warrants (series TO 3). It details the subscription price, exercise dates, dilution impact, and instructions for shareholders to exercise their warrants. This falls under the category of capital and financing updates, as it relates to the issuance of new shares and the management of the company's capital structure through a warrant program.
2025-04-01 English
Nyttjandeperioden för teckningsoptioner serie TO 3 inleds idag
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Immunovia AB announcing the commencement of the exercise period for warrants (serie TO 3). It details the terms of the warrants, the exercise period, subscription price, and instructions for shareholders. This falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the conversion of warrants into new shares and the resulting impact on capital structure.
2025-04-01 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage (11.58098%) by an entity (Avanza Bank Holding AB for Avanza Pension) in Immunovia AB (publ). It specifies the transaction date (2025-02-25), the reason ('Aktielån' - Stock loan), and the resulting number of shares and voting rights. This structure, focusing on insider/major shareholder transactions and crossing ownership thresholds, strongly aligns with the definition of a Director's Dealing or Major Shareholding Notification. Since the transaction involves a major shareholder crossing a threshold (10%) due to a stock loan return, it fits the 'Major Shareholding Notification' (MRQ) category best, as it reports the resulting holding level after a change, rather than just a director's personal trade (DIRS). The document is a formal notification published on 2025-02-26.
2025-02-26 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'BOKSLUTSKOMMUNIKÉ 2024' (Year-end Report 2024) and contains comprehensive financial data, including income statements, cash flow, and balance sheet metrics for the fourth quarter and full year 2024. It also includes a CEO letter, operational highlights, and forward-looking statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial analysis and results for a specific period. Q4 2024
2025-02-25 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.